Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Alvotech (ALVO)
USD3.34
+0.04 (+1.06%)
IS NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
Saemundargata 15-19 102
Luxembourg, IS
Luxembourg, IS
CEO
Lisa Graver
Website
alvotech.com
IPO
2022-06-16
CIK 1898416 ISIN LU2458332611
Also trades on
NASDAQ Global Market · ALVO (USD)
NASDAQ Global Market · ALVOW (USD)
Description
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.34
+0.04 (+1.06%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
678.5K
Beta
0.21
Float Shares
114.09M
Free Float %
36.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.18% | -2.05% | -4.57% | -19.32% | -35.02% | -34.89% | -66.40% | -60.75% | -70.15% | -70.15% | -70.15% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
3.34
Low
5.00
+49.9%
Consensus
7.50
+124.9%
Median
7.50
+124.9%
High
10.00
+199.9%
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 6 |
9.50
+184.9%
|
| All Time | 10 |
12.60
+277.8%
|
Quality scores
Altman Z-Score
-1.54
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+19.7% ★ Q1'26: -20.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+111.5% ★ Q1'26: -99.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-15.3% Q1'26: -63.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+48.7% ★ Q1'26: +9.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+17.3% ★ Q1'26: +3.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+4.2% Q1'26: +5.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.48× Q1'26: 18.33× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 3 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
83.03M
est: 108.84M (-23.7%)
|
91.43M
est: 308.73M (-70.4%)
|
489.68M
est: 454.43M (+7.8%)
|
586.32M
est: 581.24M (+0.9%)
|
622.73M
610.80M – 641.62M
+7.1% YoY
|
754.61M
700.50M – 844.09M
+21.2% YoY
|
958.09M
940.86M – 975.33M
+27.0% YoY
|
1.24B
1.17B – 1.35B
+29.2% YoY
|
1.46B
1.39B – 1.59B
+18.2% YoY
|
| EBITDA |
-439.80M
est: -77.41M (-468.1%)
|
-493.67M
est: -123.78M (-298.8%)
|
-32.28M
est: -182.20M (+82.3%)
|
323.39M
est: -233.04M (+238.8%)
|
-249.68M
-257.25M – -244.89M
-7.1% YoY
|
-302.55M
-338.43M – -280.86M
-21.2% YoY
|
-384.14M
-391.05M – -377.23M
-27.0% YoY
|
-496.36M
-540.26M – -470.20M
-29.2% YoY
|
-586.58M
-638.45M – -555.66M
-18.2% YoY
|
| EBIT |
-460.21M
est: -89.57M (-413.8%)
|
-517.88M
est: -162.27M (-219.2%)
|
-63.58M
est: -238.85M (+73.4%)
|
285.54M
est: -305.50M (+193.5%)
|
-327.31M
-337.24M – -321.04M
-7.1% YoY
|
-396.62M
-443.65M – -368.19M
-21.2% YoY
|
-503.58M
-512.64M – -494.52M
-27.0% YoY
|
-650.70M
-708.24M – -616.40M
-29.2% YoY
|
-768.96M
-836.96M – -728.43M
-18.2% YoY
|
| Net Income |
-513.58M
est: -306.90M (-67.3%)
|
-551.73M
est: -734.22M (+24.9%)
|
-231.86M
est: -35.85M (-546.8%)
|
27.92M
est: -22.68M (+223.1%)
|
8.68M
-69.42M – 86.77M
+138.3% YoY
|
62.92M
-2.86M – 128.71M
+625.2% YoY
|
184.84M
51.09M – 294.94M
+193.7% YoY
|
301.53M
280.87M – 336.19M
+63.1% YoY
|
463.46M
431.70M – 516.74M
+53.7% YoY
|
| SGA |
186.74M
est: 138.13M (+35.2%)
|
73.04M
est: 346.80M (-78.9%)
|
61.45M
est: 510.47M (-88.0%)
|
90.95M
est: 652.91M (-86.1%)
|
699.52M
686.11M – 720.73M
+7.1% YoY
|
847.66M
786.88M – 948.17M
+21.2% YoY
|
1.08B
1.06B – 1.10B
+27.0% YoY
|
1.39B
1.32B – 1.51B
+29.2% YoY
|
1.64B
1.56B – 1.79B
+18.2% YoY
|
| EPS |
-2.60
est: -1.15 (-127.0%)
|
-2.43
est: -2.57 (+5.5%)
|
-0.87
est: -0.13 (-593.3%)
|
0.10
est: -0.08 (+223.1%)
|
0.06
-0.25 – 0.31
+176.5% YoY
|
0.22
-0.01 – 0.46
+246.1% YoY
|
0.52
0.18 – 1.06
+140.5% YoY
|
1.08
1.01 – 1.20
+108.7% YoY
|
1.66
1.55 – 1.85
+53.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
9.01M
OE per share TTM
0.00
Owner's Yield
0.97%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
128.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
9
Total invested
795.6K
Insider transactions (90d)
0
Beneficial owners (>5%)
18
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Aztiq Fund I SCSp | 98.65M | 40.49% | — | 98.65M | — | 98.65M | OO | — | 2022-07-05 | ↗ |
| 2 | Aztiq Pharma Partners S.à r.l. | 98.65M | 40.49% | — | 98.65M | — | 98.65M | OO | — | 2022-07-05 | ↗ |
| 3 | Floki GP S.à r.l. | 98.65M | 40.49% | — | 98.65M | — | 98.65M | OO | — | 2022-07-05 | ↗ |
| 4 | Alvogen Lux Holdings S.à r.l. | 86.44M | 35.50% | — | 86.44M | — | 86.44M | CO | — | 2022-06-27 | ↗ |
| 5 | Celtic Holdings S.C.A. | 86.44M | 35.50% | — | 86.44M | — | 86.44M | CO | — | 2022-06-27 | ↗ |
| 6 | YA Global Investments II , LP | 27.04M | 9.99% | — | 27.04M | — | 27.04M | OO | Delaware | 2022-06-22 | ↗ |
| 7 | YA II PN, Ltd. | 27.04M | 9.99% | — | 27.04M | — | 27.04M | OO | Delaware | 2022-06-22 | ↗ |
| 8 | Atlas OCM Holdings, LLC | 14.87M | 5.87% | — | 14.87M | — | 14.87M | OO | — | 2023-02-14 | ↗ |
| 9 | Brookfield Asset Management ULC | 14.87M | 5.87% | — | 14.87M | — | 14.87M | OO | — | 2023-02-14 | ↗ |
| 10 | Oaktree Capital Group Holdings GP, LLC | 14.87M | 5.87% | — | 14.87M | — | 14.87M | OO | — | 2023-02-14 | ↗ |
| 11 | Oaktree Capital Management GP, LLC | 13.60M | 5.37% | — | 13.60M | — | 13.60M | OO | — | 2023-02-14 | ↗ |
| 12 | Oaktree Capital Management, L.P. | 13.60M | 5.37% | — | 13.60M | — | 13.60M | PN | — | 2023-02-14 | ↗ |
| 13 | Oaktree Acquisition Holdings II GP, Ltd. | 10.92M | 4.31% | — | 10.92M | — | 10.92M | CO | — | 2023-02-14 | ↗ |
| 14 | Oaktree Acquisition Holdings II, L.P. | 10.92M | 4.31% | — | 10.92M | — | 10.92M | PN | — | 2023-02-14 | ↗ |
| 15 | Oaktree Capital II GP LLC | 1.27M | 0.51% | — | 1.27M | — | 1.27M | OO | — | 2023-02-14 | ↗ |
| 16 | Oaktree Capital II, L.P. | 1.27M | 0.51% | — | 1.27M | — | 1.27M | PN | — | 2023-02-14 | ↗ |
| 17 | Oaktree Fund Advisors, LLC | 1.27M | 0.51% | — | 1.27M | — | 1.27M | OO | — | 2023-02-14 | ↗ |
| 18 | Oaktree Specialty Lending Corporation | 1.27M | 0.51% | — | 1.27M | — | 1.27M | CO | — | 2023-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
9
-41 vs prev Q
New positions
2
Closed positions
43
Increased
8
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 4.49M +141.9K (+3.3%) | 22.56M -12.9M (-36.4%) | 1.50% -0.051 pp | 0.00% 0.000 pp | USD9.29 -44.8% | 10 qtrs — |
| 2 | BRACEBRIDGE CAPITAL, LLC | 2.71M +— (+0.0%) | 13.88M -8.3M (-37.4%) | 0.90% -0.061 pp | 0.45% -0.718 pp | USD8.21 -37.5% | 15 qtrs — |
| 3 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.43M -19.6K (-1.3%) | 7.36M -4.5M (-38.2%) | 0.48% -0.039 pp | 0.00% -0.001 pp | USD9.61 -46.6% | 4 qtrs — |
| 4 | LITTLEJOHN & CO LLC | 1.32M +— (+0.0%) | 6.76M -4.0M (-37.4%) | 0.44% -0.030 pp | 3.52% -1.924 pp | USD12.83 -60.0% | 12 qtrs — |
| 5 | BLACKROCK, INC. | 1.18M +369.9K (+45.9%) | 6.03M -569.0K (-8.6%) | 0.39% +0.105 pp | 0.00% +0.000 pp | USD10.67 -51.9% | 5 qtrs — |
| 6 | POINTSTATE CAPITAL LP | 1.05M +— (+0.0%) | 5.38M -3.2M (-37.4%) | 0.35% -0.024 pp | 0.08% -0.049 pp | USD12.69 -59.6% | 7 qtrs — |
| 7 | LEGAL & GENERAL GROUP PLC | 581.6K +54.7K (+10.4%) | 2.92M -1.4M (-32.5%) | 0.19% +0.006 pp | 0.00% 0.000 pp | USD11.30 -54.6% | 7 qtrs — |
| 8 | OAKTREE CAPITAL MANAGEMENT LP | 533.7K -1.0M (-65.9%) | 2.02M -10.8M (-84.2%) | 0.18% -0.378 pp | 0.03% -0.161 pp | USD9.25 -44.5% | 15 qtrs — |
| 9 | MILLENNIUM MANAGEMENT LLC | 357.2K +337.4K (+1,707.7%) | 1.83M +1.7M (+1,032.3%) | 0.12% +0.112 pp | 0.00% +0.001 pp | USD5.42 -5.4% | 7 qtrs — |
| 10 | GOLDMAN SACHS GROUP INC | 259.5K +122.1K (+88.8%) | 1.33M +205.7K (+18.3%) | 0.09% +0.038 pp | 0.00% +0.000 pp | USD7.34 -30.1% | 7 qtrs — |
| 11 | MORGAN STANLEY | 255.2K +80.2K (+45.8%) | 1.31M -124.5K (-8.7%) | 0.09% +0.023 pp | 0.00% +0.000 pp | USD9.79 -47.6% | 15 qtrs — |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 254.9K +24.7K (+10.7%) | 1.31M -578.0K (-30.7%) | 0.08% +0.003 pp | 0.00% +0.000 pp | USD11.27 -54.5% | 12 qtrs — |
| 13 | FARALLON CAPITAL MANAGEMENT LLC | 199.7K +— (+0.0%) | 1.02M -611.0K (-37.4%) | 0.07% -0.005 pp | 0.00% -0.002 pp | USD11.90 -56.9% | 6 qtrs — |
| 14 | UBS GROUP AG | 136.1K +109.3K (+408.9%) | 698.0K +479.0K (+218.7%) | 0.05% +0.036 pp | 0.00% +0.000 pp | USD6.72 -23.7% | 15 qtrs — |
| 15 | JANE STREET GROUP, LLC | 92.3K +92.3K (+100.0%) | 473.6K +473.6K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.000 pp | USD5.13 +0.0% | 1 qtrs NEW |
| 16 | OAKTREE FUND ADVISORS, LLC | 146.8K +70.8K (+93.2%) | 397.1K -225.5K (-36.2%) | 0.05% +0.022 pp | 0.73% -0.412 pp | USD7.74 -33.7% | 15 qtrs — |
| 17 | INVESCO LTD. | 73.4K +26.8K (+57.5%) | 376.3K -5.1K (-1.3%) | 0.02% +0.008 pp | 0.00% +0.000 pp | USD8.20 -37.4% | 5 qtrs — |
| 18 | ULLAND INVESTMENT ADVISORS, LLC | 72.5K +61.3K (+544.4%) | 372.0K +280.0K (+304.3%) | 0.02% +0.020 pp | 0.30% +0.229 pp | USD5.60 -8.4% | 2 qtrs — |
| 19 | TEMPUS WEALTH PLANNING, LLC | 53.9K +20.1K (+59.4%) | 276.4K -467.0 (-0.2%) | 0.02% +0.006 pp | 0.06% 0.000 pp | USD9.40 -45.4% | 5 qtrs — |
| 20 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 51.0K -3.9K (-7.0%) | 261.7K -187.7K (-41.8%) | 0.02% -0.003 pp | 0.02% -0.017 pp | USD12.89 -60.2% | 5 qtrs — |
| 21 | BANK OF AMERICA CORP /DE/ | 35.5K +20.2K (+131.4%) | 182.1K +56.5K (+44.9%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD7.34 -30.1% | 12 qtrs — |
| 22 | — | 35.4K +— (+0.0%) | 181.6K -108.3K (-37.4%) | 0.01% -0.001 pp | 0.11% -0.085 pp | USD9.12 -43.8% | 3 qtrs — |
| 23 | RENAISSANCE TECHNOLOGIES LLC | 25.6K -6.6K (-20.4%) | 131.3K -132.1K (-50.1%) | 0.01% -0.003 pp | 0.00% 0.000 pp | USD8.19 -37.4% | 2 qtrs — |
| 24 | JPMORGAN CHASE & CO | 24.2K -206.0 (-0.8%) | 124.4K -75.9K (-37.9%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD12.00 -57.3% | 12 qtrs — |
| 25 | STIFEL FINANCIAL CORP | 21.0K +21.0K (+100.0%) | 107.7K +107.7K (+100.0%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD5.13 +0.0% | 1 qtrs NEW |
| 26 | AMUNDI | 19.4K +— (+0.0%) | 99.6K -67.0K (-40.2%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD10.56 -51.4% | 8 qtrs — |
| 27 | BARCLAYS PLC | 15.5K -5.7K (-27.1%) | 79.3K -94.4K (-54.3%) | 0.01% -0.002 pp | 0.00% +0.000 pp | USD12.13 -57.7% | 5 qtrs — |
| 28 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 15.2K +3.1K (+25.7%) | 78.0K -21.1K (-21.3%) | 0.01% +0.001 pp | 0.00% 0.000 pp | USD10.64 -51.8% | 5 qtrs — |
| 29 | POINT72 ASSET MANAGEMENT, L.P. | 14.8K +14.8K (+100.0%) | 76.1K +76.1K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.000 pp | USD5.13 +0.0% | 1 qtrs NEW |
| 30 | CITIGROUP INC | 14.4K +8.4K (+138.7%) | 73.7K +24.4K (+49.5%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD6.91 -25.8% | 4 qtrs — |
| 31 | RICHMOND BROTHERS, INC. | 14.0K +— (+0.0%) | 71.6K -42.7K (-37.4%) | 0.00% 0.000 pp | 0.05% -0.027 pp | USD12.36 -58.5% | 7 qtrs — |
| 32 | PROSHARE ADVISORS LLC | 13.8K +2.7K (+24.0%) | 70.9K -20.4K (-22.3%) | 0.00% +0.001 pp | 0.00% 0.000 pp | USD7.60 -32.5% | 5 qtrs — |
| 33 | BRINKER CAPITAL INVESTMENTS, LLC | 12.0K +770.0 (+6.8%) | 61.8K -30.5K (-33.1%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD7.99 -35.8% | 2 qtrs — |
| 34 | BNP PARIBAS ARBITRAGE, SNC | 6.8K +2.9K (+75.3%) | 34.6K +3.1K (+9.8%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD9.64 -46.8% | 5 qtrs — |
| 35 | GF FUND MANAGEMENT CO. LTD. | 6.2K -584.0 (-8.7%) | 31.6K -23.6K (-42.8%) | 0.00% 0.000 pp | 0.00% -0.001 pp | USD12.59 -59.3% | 5 qtrs — |
| 36 | AQUATIC CAPITAL MANAGEMENT LLC | 4.6K +4.6K (+100.0%) | 23.4K +23.4K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.001 pp | USD5.13 +0.0% | 1 qtrs NEW |
| 37 | SCULPTOR CAPITAL LP | 33.8K +— (+0.0%) | 19.9K -39.7K (-66.6%) | 0.01% -0.001 pp | 0.00% -0.001 pp | USD9.80 -47.7% | 15 qtrs — |
| 38 | EMPOWERED FUNDS, LLC | 3.7K +3.7K (+100.0%) | 19.0K +19.0K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD5.13 +0.0% | 1 qtrs NEW |
| 39 | TOWER RESEARCH CAPITAL LLC (TRC) | 3.3K -2.8K (-45.8%) | 17.2K -33.4K (-66.1%) | 0.00% -0.001 pp | 0.00% -0.001 pp | USD8.78 -41.6% | 5 qtrs — |
| 40 | ADVISOR GROUP HOLDINGS, INC. | 1.2K +173.0 (+16.7%) | 6.2K -2.3K (-26.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.02 -36.0% | 7 qtrs — |
| 41 | CAPITAL ANALYSTS, LLC | 932.00 +— (+0.0%) | 5.0K -3.0K (-37.5%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD9.67 -46.9% | 4 qtrs — |
| 42 | DAIWA SECURITIES GROUP INC. | 1.0K +— (+0.0%) | 5.0K -3.0K (-37.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD12.71 -59.6% | 5 qtrs — |
| 43 | RIALTO WEALTH MANAGEMENT, LLC | 600.00 +— (+0.0%) | 3.1K -1.8K (-37.4%) | 0.00% +0.000 pp | 0.00% -0.001 pp | USD8.19 -37.4% | 2 qtrs — |
| 44 | ZURCHER KANTONALBANK (ZURICH CANTONALBANK) | 585.00 +— (+0.0%) | 3.0K -1.8K (-37.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD9.67 -46.9% | 4 qtrs — |
| 45 | LARSON FINANCIAL GROUP LLC | 313.00 +125.0 (+66.5%) | 1.6K +66.0 (+4.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.34 -30.1% | 9 qtrs — |
| 46 | ROYAL BANK OF CANADA | 169.00 -3.3K (-95.1%) | 1.0K -28.0K (-96.6%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD8.54 -39.9% | 5 qtrs — |
| 47 | SMARTLEAF ASSET MANAGEMENT LLC | 162.00 +162.0 (+100.0%) | 818.00 +818.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.13 +0.0% | 1 qtrs NEW |
| 48 | NORTH STAR INVESTMENT MANAGEMENT CORP. | 151.00 +95.0 (+169.6%) | 775.00 +316.0 (+68.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.26 -18.1% | 2 qtrs — |
| 49 | ALLWORTH FINANCIAL LP | 150.00 +— (+0.0%) | 770.00 -459.0 (-37.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.19 -37.4% | 2 qtrs — |
| 50 | SBI SECURITIES CO., LTD. | 10.00 +9.0 (+900.0%) | 51.00 +43.0 (+537.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.40 -5.0% | 2 qtrs — |
| 51 | STATE OF WYOMING | — -6.6K (-100.0%) | — -54.1K (-100.0%) | 0.00% -0.002 pp | 0.00% -0.006 pp | USD— | 2 qtrs SOLD |
| 52 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | — -1.7K (-100.0%) | — -14.0K (-100.0%) | 0.00% -0.001 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 53 | SWAN CAPITAL LLC | — -100.0 (-100.0%) | — -819.0 (-100.0%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 54 | TBH GLOBAL ASSET MANAGEMENT, LLC | — -35.5K (-100.0%) | — -290.7K (-100.0%) | 0.00% -0.013 pp | 0.00% -0.057 pp | USD— | 7 qtrs SOLD |
| 55 | CITADEL ADVISORS LLC | — -42.2K (-100.0%) | — -345.6K (-100.0%) | 0.00% -0.015 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 56 | BARE FINANCIAL SERVICES, INC | — -62.0 (-100.0%) | — -508.0 (-100.0%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 57 | WELLS FARGO & COMPANY/MN | — -6.4K (-100.0%) | — -52.4K (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 58 | WOLVERINE ASSET MANAGEMENT LLC | — -23.1K (-100.0%) | — -188.9K (-100.0%) | 0.00% -0.008 pp | 0.00% -0.001 pp | USD— | 6 qtrs SOLD |
| 59 | XTX TOPCO LTD | — -27.2K (-100.0%) | — -223.1K (-100.0%) | 0.00% -0.010 pp | 0.00% -0.012 pp | USD— | 2 qtrs SOLD |
| 60 | EVERSOURCE WEALTH ADVISORS, LLC | — -134.0 (-100.0%) | — -1.1K (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 61 | NORTHERN TRUST CORP | — -95.9K (-100.0%) | — -785.3K (-100.0%) | 0.00% -0.034 pp | 0.00% 0.000 pp | USD— | 8 qtrs SOLD |
| 62 | MARINER, LLC | — -10.8K (-100.0%) | — -88.2K (-100.0%) | 0.00% -0.004 pp | 0.00% 0.000 pp | USD— | 12 qtrs SOLD |
| 63 | MAGNETAR FINANCIAL LLC | — -10.5K (-100.0%) | — -85.7K (-100.0%) | 0.00% -0.004 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 64 | LPL FINANCIAL LLC | — -41.2K (-100.0%) | — -337.7K (-100.0%) | 0.00% -0.015 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 65 | JONES FINANCIAL COMPANIES LLLP | — -451.0 (-100.0%) | — -3.8K (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 66 | GWN SECURITIES INC. | — -19.6K (-100.0%) | — -160.5K (-100.0%) | 0.00% -0.007 pp | 0.00% -0.037 pp | USD— | 2 qtrs SOLD |
| 67 | QUADRATURE CAPITAL LTD | — -22.7K (-100.0%) | — -185.9K (-100.0%) | 0.00% -0.008 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
| 68 | GAMMA INVESTING LLC | — -225.0 (-100.0%) | — -1.8K (-100.0%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 69 | FARTHER FINANCE ADVISORS, LLC | — -273.0 (-100.0%) | — -2.2K (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 70 | ROYCE & ASSOCIATES LP | — -124.3K (-100.0%) | — -1.0M (-100.0%) | 0.00% -0.044 pp | 0.00% -0.010 pp | USD— | 7 qtrs SOLD |
| 71 | MARSHALL WACE, LLP | — -136.9K (-100.0%) | — -1.1M (-100.0%) | 0.00% -0.049 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 19 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Genomics Immunology and Healthcare ETF IDNA | 0.41% | 797.0K | 0.47% |
| 2 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.07% | 325.8K | 0.40% |
| 3 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.07% | 52.6K | 0.19% |
| 4 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.07% | 51.6K | 0.35% |
| 5 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.07% | 770.2K | 0.35% |
| 6 | ProShares Ultra Nasdaq Biotechnology BIB | 0.04% | 34.3K | 1.19% |
| 7 | iShares Biotechnology ETF IBB | 0.03% | 2.80M | 0.44% |
| 8 | T. Rowe Price International Equity Research ETF TIER | 0.02% | 5.4K | 0.38% |
| 9 | Invesco RAFI US 1500 Small-Mid ETF PRFZ | 0.01% | 240.2K | 0.34% |
| 10 | Vanguard Emerging Markets Ex-China ETF VEXC | 0.00% | 11.0K | 0.07% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
282.2K
Shares Outstanding
312.05M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Vilhelm Robert Wessman | Founder & Executive Chairman | 3M | male |
| Lisa Graver | Chief Executive Officer | 186.0K | female |
| Balaji Venkataramanan Prasad | Chief Strategy Officer | — | — |
| Benedikt Stefansson | Vice President of Investor Relations and Global Communications | — | male |
| Johann Johannsson | Executive Vice President of Capital Markets and M&A | — | male |
| Joseph E. McClellan | Chief Operating Officer | — | male |
| Agne Pasko | Vice President & Head of Business Development | — | female |
| Linda Jonsdottir | Chief Financial Officer | — | female |
| Sarah Macleod | Head of Global Communications | — | female |
| Tanya Zharov | General Counsel | — | female |
| Kathryn Gunnarsson | Senior Vice President of Global Talent & People Experience | — | female |
| Anthony Maffia | Chief Quality & Regulatory Officer | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALVO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
